Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
230 participants
OBSERVATIONAL
2020-05-07
2023-05-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope. Coagulation tests will be performed on BCS XP analyzers.
An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will be used to detect the ability of antibodies from patients' serum to neutralize the virus and thus potential protection against re-infection. The system is quantitative, meaning that the titer of such antibodies could be determined, and thus the potential level of protection would be evaluated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for SARS-CoV-2).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Chemistry, Slovenia
UNKNOWN
The University Clinic of Pulmonary and Allergic Diseases Golnik
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Korošec
Assoc Prof Peter Korošec, BSc (Biol), PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Korošec, PhD
Role: PRINCIPAL_INVESTIGATOR
Head of the Laboratory for Clinical Immunology and Molecular Genetics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Clinic of Respiratory and Allergic Diseases Golnik
Golnik, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Peter Korošec, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Golnik_Covid-19
Identifier Type: -
Identifier Source: org_study_id